key: cord-0806528-z3ktkgyp
authors: Loyal, L.; Braun, J.; Henze, L.; Kruse, B.; Dingeldey, M.; Reimer, U.; Kern, F.; Schwarz, T.; Mangold, M.; Unger, C.; Doerfler, F.; Kadler, S.; Rosowski, J.; Guercan, K.; Uyar-Aydin, Z.; Frentsch, M.; Kurth, F.; Schnatbaum, K.; Eckey, M.; Hippenstiel, S.; Hocke, A.; Mueller, M. A.; Sawitzki, B.; Miltenyi, S.; Paul, F.; Mall, M. A.; Wenschuh, H.; Voigt, S.; Drosten, C.; Lauster, R.; Lachmann, N.; Sander, L.-E.; Corman, V. M.; Roehmel, J.; Meyer-Arndt, L. A.; Thiel, A. M.; Giesecke-Thiel, C.
title: Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination
date: 2021-04-05
journal: nan
DOI: 10.1101/2021.04.01.21252379
sha: c545fb497fa67f3a49fd855f60d115ad60bb52d3
doc_id: 806528
cord_uid: z3ktkgyp

While evidence for pre-existing SARS-CoV-2-cross-reactive CD4+ T cells in unexposed individuals is increasing, their functional significance remains unclear. Here, we comprehensively determined SARS-CoV-2-cross-reactivity and human coronavirus-reactivity in unexposed individuals. SARS-CoV-2-cross-reactive CD4+ T cells were ubiquitous, but their presence decreased with age. Within the spike glycoprotein fusion domain, we identified a universal immunodominant coronavirus-specific peptide epitope (iCope). Pre-existing spike- and iCope-reactive memory T cells were efficiently recruited into mild SARS-CoV-2 infections and their abundance correlated with higher IgG titers. Importantly, the cells were also reactivated after primary BNT162b2 COVID-19 mRNA vaccination in which their kinetics resembled that of secondary immune responses. Our results highlight the functional importance of pre-existing spike-cross-reactive T cells in SARS-CoV-2 infection and vaccination. Abundant spike-specific cross-immunity may be responsible for the unexpectedly high efficacy of current vaccines even with single doses and the high rate of asymptomatic/mild infection courses.

While evidence for pre-existing SARS-CoV-2-cross-reactive CD4 + T cells in unexposed individuals is increasing, their functional significance remains unclear. Here, we comprehensively determined SARS-CoV-2-cross-reactivity and human coronavirus-reactivity in unexposed individuals. SARS-CoV-2-cross-reactive CD4 + T cells were ubiquitous, but their presence decreased with age. Within the spike glycoprotein fusion domain, we identified a universal immunodominant coronavirus-specific peptide epitope (iCope). Pre-existing spikeand iCope-reactive memory T cells were efficiently recruited into mild SARS-CoV-2 infections and their abundance correlated with higher IgG titers. Importantly, the cells were also reactivated after primary BNT162b2 COVID-19 mRNA vaccination in which their kinetics resembled that of secondary immune responses. Our results highlight the functional importance of pre-existing spike-cross-reactive T cells in SARS-CoV-2 infection and vaccination. Abundant spike-specific cross-immunity may be responsible for the unexpectedly high efficacy of current vaccines even with single doses and the high rate of asymptomatic/mild infection courses.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a global pandemic challenging economy and health systems. In the majority of infected individuals, coronavirus disease 2019 (COVID-19) manifests in asymptomatic or mild phenotypes. However, severe and fatal disease occurs in about 5% of those infected and are primarily associated with age and comorbidities such as cardiovascular, pulmonary and kidney diseases and diabetes (1). Initially, it was assumed that SARS-CoV-2 encountered an immunologically unprotected population, however, SARS-CoV-2 displays considerable homologies with endemic, seasonal common cold endemic coronaviruses (collectively referred to as 'HCoV') (2, 3) . There is now firm evidence for the cellular and humoral cross-reactivity to SARS-CoV-2 (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , although the role of cross-reactive immunity in SARS-CoV-2 infection is controversial, and potential negative effects have been discussed (2, 8, 15, 16) . However, it has been reported that recent HCoV infection is associated with less severe COVID-19, suggesting a protective role (17) . Thus, a better understanding of the extent and impact of crossimmunity in SARS-CoV-2 infection and vaccination is critical, as cognate cross-immunity would influence a vaccination regimen which should then be adjusted to achieve global population immunity in the most expeditious manner.

Here we determined the functional role of pre-existing SARS-CoV-2 and HCoV-reactive CD4 + T cells at a previously unattained resolution. We demonstrate broad T cell cross-reactivity in unexposed individuals with spike glycoprotein (spike) serving as one of the immunodominant targets. This cross-immunity decreased with age. Importantly, we identified an immunodominant Coronavirus peptide epitope (iCope) located within the fusion domain of spike recognized by CD4 + T cells in 20% of unexposed individuals, 50-60% of SARS-CoV-2 convalescents and 97% of BNT162b2 vaccinated individuals. iCope and spike-cross-reactive T cells were recruited into primary SARS-CoV-2 infection immune responses and also profoundly into BNT162b2 COVID-19 mRNA vaccination responses. Finally, cross-reactive immunity exhibited secondary response kinetics upon primary vaccination and abundance of pre-existing cross-reactive T cells correlated with high functional avidity already early in the immune response as well as with the early induction and stabilization of S1 IgG antibody titers. Our results demonstrate a role of cross-reactive CD4 + T cells in SARS-CoV-2 infection and vaccination and add new information on the discussion of implementing both single-dose vaccination of healthy adults and two-dose vaccination of the elderly.

To determine the extent of cellular cross-reactivity, we stimulated CD4 + T cells of 60 unexposed healthy donors and 59 COVID-19 convalescents as controls (Table 1) with the complete SARS-CoV-2 orfeome (Fig. 1A) . The SARS-CoV-2 orfeome consists of 11 ORFs (NCBI), five of which (ORF1a/b, NCAP, spike, VEMP and VME) are also found in HCoVs 229E, OC43, NL63 and HKU1, with ORF1a/b coding for a total of 16 non-structural proteins (NSPs). Amino acid sequence alignment revealed discrete stretches of high homology in almost all SARS-CoV-2 proteins to the corresponding proteins in HCoVs. Parts of the ORF1a/b including NSP8, NSP10 and NSP12-16 displayed the highest frequencies of homology and thus potential cross-reactive epitopes to all HCoVs (Fig. S1a) . COVID-19 convalescents displayed CD4 + T cells reacting strongly against spike N-terminal S-I (amino acid residues 1-643) and Cterminal S-II (amino acid residues 633-1273), NCAP, and VME peptide pools (Fig. 1A, B) . avidity should be distinguishable from non-cognate cross-reactivity with higher probability of low functional avidity by analyzing the frequency of CD3 low T cells among CD4 + T cells activated via their TCR. Accordingly, when stimulated with the peptide pools of the autoantigen ACTIN or vaccinia virus (VACV, unvaccinated donors, Fig. 2B ), the few reactive T cells exhibited only low non-cognate reactivity, characterized by low antigen avidity with CD3 low frequencies below 20% (Fig. 2C, Fig. S2 ). By contrast, T cell responses to the hepatitis B vaccine as well as to recurrent infections (Influenza A, Adenovirus and CMV, Fig. 2B ) were characterized by high frequencies of reactive T cells and high frequencies of high avidity CD3 low cells (Fig. 2C ). After stimulations with spike S-I/S-II peptide pools, COVID-19 convalescents showed high frequencies of spike S-I and S-II-activated CD4 + T cells that largely lacked CD3 expression (Fig. 2D) . In unexposed individuals, the frequency of CD3 low cells among spike S-I and S-II-activated CD4 + T cells was markedly lower, but significantly higher frequencies of CD3 low cells were present among S-II-than among S-I-activated CD4 + T cells across all age groups (Fig. 2D) . These results are consistent with the high homology of the Cterminal S-II portion of SARS-CoV-2 spike to the analogous S-II portion of HCoV spike. These results indicate that spike S-II (cross)-reactive CD4 + T cells comprise cells with high functional avidity.

We hypothesized that previous HCoV exposures induce cognate cross-reactive CD4 + T cells. Therefore, we next characterized CD4 + T cell immunity to HCoV spike in unexposed individuals and COVID-19 convalescents, again grouped by age. HCoV-S-I and S-II-reactive CD4 + T cells were more readily detectable than SARS-CoV-2 spike-specific T-cells and found in 80% (S-I) and 98% (S-II) of SARS-CoV-2 unexposed individuals, respectively (Fig. 3A) . However, their frequency significantly decreased with age, and in this instance this reduction was also detectable for the S-I-reactive T cells. Aggregated as a group, SARS-CoV-2 infection overall did not result in higher HCoV-S-I-/S-II-reactive T cell frequencies in COVID-19 convalescents compared to unexposed individuals. HCoV-reactive T cells were also found to decrease as a function of age. We also examined the functional avidities of HCoV-reactive CD4 + T cells (Fig. 3B ). Among HCoV spike S-I-and S-II-reactive CD4 + T cells, high frequencies of CD3 low T cells were found, which again significantly decreased with increasing age. These results suggest a high degree of HCoV exposure of the population, leading to equally widespread cross-immunity to SARS-CoV-2 spike. HCoV-reactive CD4 + T cells frequently comprised cells with high functional avidity but significantly decreased with age. presence of OC43-or SARS-CoV-2 spike pool S-I and S-II, respectively. 6 out of 18 OC43 S-II specific short-term T cell lines displayed cross-reactivity against SARS-CoV-2 S-II (Fig. 4B) whereas OC43 S-I specific T cell lines lacked cross-reactivity against SARS-CoV-2 S-I. Next, we aimed to identify the underlying SARS-CoV-2 S-II cross-reactive epitopes. To this end, we isolated SARS-CoV-2 S-II-cross-reactive CD4 + T cells from 5 unexposed individuals at high purity, expanded the cells in vitro, and examined their specificity upon restimulation with peptide matrices. We identified two T-cell stimulating peptides (peptides 204 and 205) within S-II in all 5 donors (Fig. S3A) . Restimulation of the expanded T cell lines with single peptides and negative control peptides validated the specificity for peptides 204 (N´-SKRSFIEDLLFNKVT-C´) and 205 (N´-FIEDLLFNKVTLADA-C´) (Fig. S3B ). Only one donor responded to some of the other identified candidates (peptides 188, 189, 251; fig. S3B ). Sequence alignment revealed that S-II peptides 204 and 205 were located in a region of spike characterized by high homology with HCoV (Fig. S3C ). The peptides 204 and 205 largely overlapped and differed in only 3 amino acids (aa). By designing 15 aa peptides covering the intersection of both peptides we identified the fusion peptide domain 1 sequence N´-SFIEDLLFNKVTLAD-C´ (aa 816-830) as the immunodominant Coronavirus peptide epitope hereafter referred to as "iCope" (peptide 204_3, Fig. S3D ). We next examined direct ex vivo T cell reactivity against iCope compared to a control peptide 284 (aa 1133-1147) and the SARS-CoV-2 spike S-II peptide pool in 48 unexposed individuals and 22 COVID-19 convalescents. Note that iCope-reactive CD4 + T cells were detected in 50% of convalescents and 20% of unexposed individuals with significantly higher frequency in the former (Fig. 4C ). Antibodies to the SARS-CoV-2 spike amino acid residues 815-823 (peptide 204_-1) were previously reported in COVID-19 patients but also in unexposed individuals (21) . By examining sera from iCope-T-cell-assay-responders and non-responders we detected 204_-1 binding antibodies in all individuals, however, significantly higher concentration of these antibodies was found in COVID-19 convalescents with substantially more iCope-reactive T cells (Fig. 4D ). HLAtyping of n = 308 unexposed study participants revealed that among the most frequent alleles (found in >10% of individuals in the study) definite iCope responders (stim. index ≥ 3) compared to definite non-responders (stim. index ≤ 1.5) were more frequently positive for HLA-DPB1*02:01, HLA-DPB1*04:02 and, especially homozygous expression of HLA-DPB1*04:01 (Fig. 4E ). Since HLA-DPA1*01:03 was found in 100% of the responders and 94.8% of the non-responders we investigated if combinations of HLA-DPA1*01:03 and HLA-DPB1*02:01/DPB1*04:01/DPB1*04:02 were likely to present iCope or fragments thereof. HLA-peptide-binding predictions (www.IEDB.org) identified excellent potential binders (Fig.  S3E ) which was also true for the homologous peptide of iCope in other HCoVs (Fig. S3F ).

SARS-CoV-2 and all 4 HCoVs was performed. We aimed to re-sample patients on day (d) 7, d14, d21 and >d35 after the assumed infection day by estimating the infection day to be three days before symptom onset. 17 cases of acute primary SARS-CoV-2 infection were identified (Table 2, Fig. 5 ). All 17 patients showed mild COVID-19 disease progression and immediately detectable viral titers (Fig. S4 ). Robust CD4 + T cell responses specific of SARS-CoV-2 spike S-I and S-II were detected and the proportions of HLADR + CD38 + cells among CD40L + 4-1BB + CD4 + T cells significantly increased on follow up time points 1 and 2 (3-16 days) indicating their in vivo activation (Fig. 5A, B) . High functional avidity CD3 low cells substantially increased during acute primary SARS-CoV-2 infection and remained at a high level when the infection had resolved (Fig. 5C ). Individuals who already had spike S-II-cross-reactive CD4 + T cells with a stimulation index above 3 at baseline showed superior high functional avidities throughout the initiation of the T cell response (Fig. 5D ). iCope-reactive T cells increased in frequency and in functional avidity in 10 of 17 donors after infection (Fig. 5E, F) . Notably, IgG antibodies against the 204_-1 peptide were boosted as early as 3-9 days (follow-up 1) after the presumed infection (Fig. 5G ). The appearance kinetics and levels of anti-S1-IgG serum antibodies varied widely, being first detectable at follow-up time point 2 and peaking after day 20 in most subjects (Fig. 5H ). Anti-S1-IgG ratios at late time points positively correlated with S-II-but not S-Icross-reactive T cell levels at d0 suggesting that pre-existing cross-reactive CD4 + T cells enhanced SARS-CoV-2-specific humoral immunity (Fig. 5I, left) . Moreover, the titer of neutralizing antibodies also positively correlated with S-II-but not S-I-cross-reactive CD4 + T cells at baseline, indicating a role of cross-reactive CD4 + T cells in protection (Fig. 5I , middle and right). Finally, the frequency of pre-existing HCoV-reactive CD4 + T cells increased in almost all individuals shortly after primary SARS-CoV2 infection (Fig. 5J) . There was also a concomitant increase in the frequency of CD3 low cells (Fig. 5K ) and HLADR + CD38 + cells (Fig.  5L ) among HCoV-reactive T cells, demonstrating that pre-existing HCoV-reactive cellular immunity became activated and expanded during primary SARS-CoV-2 infection. Overall, these results indicate that pre-existing SARS-CoV-2 S-II-cross-reactive T cells were recruited into primary SARS-CoV-2 immune responses in healthy unexposed individuals. The quantity and functional avidity of pre-existing cross-reactive cellular immunity corresponded to the quality and magnitude of specific cellular and humoral anti-SARS-CoV-2 responses and thus may efficiently support mild COVID-19 disease courses.

Finally, we investigated how pre-existing SARS-CoV-2 S-II-cross-reactive T cells in healthy unexposed individuals influenced the course of BNT162b2 COVID-19 spike mRNA vaccine responses. We monitored baseline-and follow up humoral-and T cell responses against SARS-CoV-2-and HCoV spike glycoproteins in 31 healthy adults who underwent primary and booster vaccination with BNT162b2 at d0 and d21. At day 21, 30 of 31 donors had seroconverted for anti-S1-IgG and all donors had seroconverted for anti-S1-IgA ( Fig. 6A ) with booster vaccination further increasing the antibody levels. BNT162b2 vaccination induced robust S-I and S-II CD4 + T cell responses in all individuals after primary vaccination which were again slightly enhanced by booster vaccination (Fig. 6B ). By contrast, the functional avidity of CD40L + 4-1BB + CD4 + T cells was again substantially increased by booster vaccination (Fig.  6D) . Moreover, at day 14 all but three donors had high frequencies of HLADR + CD38 + cells . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 5, 2021. ;  among S-I-and S-II-reactive CD4 + T cells indicating their recent in vivo activation (Fig. 6E ). Of note, kinetics of S-I-and S-II-reactive T cells differed in that S-II-reactive T cells showed a sharp increase from baseline to 7 days after vaccination but not thereafter, whereas S-I-reactive T cells again showed a marked increase from day 7 to day 14 ( Fig. 6B, C) , which is indicative of secondary response kinetics of the former and primary response kinetics of the latter (22). Frequencies of HCoV S-II-reactive T cells were significantly increased 7 days after primary vaccination (Fig. 6F) , which was in accordance with increased frequencies of HCoV S-IIreactive HLADR + CD38 + T cells (Fig. 6G) , demonstrating that cognate cross-reactive T cells were activated in response to SARS-CoV-2 spike-specific vaccination. All but 2 of 31 donors (94%) responded with high functional avidity T cells to iCope at day 7 and day 14 (Fig. 6H , I). We observed a correlation between the iCope-reactive T cell response and the S-II-reactive T cell response at d0 that was even more pronounced in the early stage of the immune response on day 7 emphasizing the importance of iCope in the anti-SARS-CoV-2 cellular immune response (Fig. 6K ). iCope-specific T cells initially contributed to up to 100% of the CD40L + 4-1BB + cells in S-II stimulations but decreased in proportion as other specificities increased during the course of the immune response (Fig. 6L ). Finally, comparable to the cellular response, a humoral response to the iCope-overlapping sequence 204_-1 was detectable upon vaccination as early as 7 days after primary vaccination (Fig. 6M ) supporting the notion of secondary response kinetics (23) for pre-existing cross-reactive immunity.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

A better understanding of how cross-reactive immunity influences COVID-19 disease severity and virus clearance is central to containment efforts as well as to the evaluation of the most efficient vaccination strategies. Non-cognate cross-reactivity has been reported but plays a minor role compared to HCoV-mediated cognate cross-reactivity (16,23). However, the clinical relevance of pre-existing cognate cross-immunity to SARS-CoV-2 has been a subject of much debate. A recent HCoV infection has been associated with less severe COVID-19 (17) . Interestingly, more than 90% of the population is HCoV seropositive, thus a large proportion of the population might have some underlying humoral immunity (24, 25). However, in prepandemic sera from PCR-validated HCoV-positive individuals, neutralizing antibodies against all HCoVs but no neutralizing antibodies to SARS-CoV-2 were found (24). In a further report, only low spike-specific cross-reactive antibody activity was detected in 5 of 34 donors with recent HCoV infection and in 1 of 31 donors without recent HCoV infection, indicating low level and fast decay of humoral cross-immunity (12) . Finally, infection with SARS-CoV-2 increased the prevalence of antibodies against seasonal HCoVs which, however, did not provide protection against SARS-CoV-2, thus drawing attention to the role of cross-reactive cellular immunity (9, 24, 25) .

Recently, cross-reactive T cells in unexposed individuals for several SARS-CoV-2 antigens utilizing predicted epitopes (4, 5) or megapools of selected peptides were identified (8, 26) . Although the 21kb long ORF1a/b accounts for the majority of the total 29.8 kb coding sequence of SARS-CoV-2, the totality of T cell responses to ORF1a/b encoded proteins in COVID-19 convalescents compared to cross-reactive T-cell responses in healthy unexposed donors had not been previously analyzed. Our work revealed significant cross-reactivity regarding ORF1a/b encoded proteins but also that most of the anti-SARS-CoV-2 reactivity was directed against spike, NCAP and VME protein. We further demonstrated that the magnitude and quality of SARS-CoV-2 cross-reactivity and HCoV-reactivity declined with age. This failure of the aging immune system to maintain HCoV-induced SARS-CoV-2 cross-reactive T cells might explain, to an extent, the significant increase in life-threatening COVID-19 disease in the older population. Our results demonstrate not only that HCoV-specific, cross-reactive T cells contributed to SARS-CoV-2 immune responses upon infection and vaccination, but also, that cognate cross-reactivity correlates with a slightly faster high quality cellular as well as enhanced humoral response. Mechanistic insights into this observation can be derived from prime-boost experiments in mice. Here, sequential administration of two antigens sharing the same carrier induces pre-existing T-cell help leading to more efficient B-cell recruitment in secondary immunization (27) . Further studies in mice showed that T cell signals early in the immune response can be limiting and that after viral infection, the presence of cognate T cell help promotes germinal center formation which is required for high affinity antibody generation (27) (28) (29) . As early induction of SARS-CoV-2 T cell reactivity has been associated with rapid viral clearance and mild disease (30), cross-reactive T cells that enhance the immune response to SARS-CoV-2 may be a correlate of immune protection, as recently discussed (31, 32) .

Upon BNT162b2 vaccination we observed immune responses that exceeded the response to SARS-CoV-2 infection in terms of T cell and antibody levels. Responses to S-II, unlike . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2021. ;  responses to the non-cross-reactive S-I, displayed a kinetics profile reminiscent of a secondary rather than a primary response (22, 23). These observations may provide an explanation for the results of current large on-going studies showing protection levels against SARS-CoV-2 infection in excess of 75% as early as 15-28 days after primary vaccination with BNT162b2 (33) . In addition, just one dose of the BNT162b2 or the Astra Zeneca ChAdOx1 vaccine reduced the risk of hospitalization by 85% and 94%, respectively, on days 28-34 post primary vaccination, indicating markedly high efficiency (34) . Interestingly, a single shot vaccination protocol based on A26 adenovirus encoded, modified spike protein from Johnson & Johnson with a reported vaccine efficiency of 66% was recently approved by the FDA and the EMA (Janssen Ad26.COV2.S (COVID-19) Vaccine VRBPAC Briefing document, FDA). Our data supports the notion that cross-immunity induced by HCoV infections may favor milder SARS-CoV-2 infection courses and furthermore provide an immunological explanation for the high clinical efficacy of SARS-CoV-2 vaccines after just one single dose. The known abundance of HCoV infections would imply that subjects with no or reduced immunity to HCoVs would be at a higher risk of failing to control early virus replication and, as a result, provide conditions favoring viral dissemination. In unexposed subjects with sufficient levels of HCoV reactivity and thus pre-existing cross-reactivity against SARS-CoV-2, a single dose of a spike protein based vaccine may provide efficient protection. However, in older people with waning HCoV reactivity and SARS-CoV-2 cross-reactivity, repeated vaccinations may be critical (35) .

The immunodominant cross-reactive peptide (iCope) that we identified here is located within the highly conserved spike fusion domain downstream of the S2′ cleavage site (36) . We demonstrate that iCope-reactive T cells were efficiently recruited into the SARS-CoV-2 response in the majority of infected and almost all vaccinated individuals. The literature reports variable but generally high frequencies of HLA-DPA1*01:03, DPB1*02:01, DPB1*04:01, and DPB1*04:02 in different populations around the world (allelefrequencies.net). The high allele frequencies of HLA-DPA1*01:03 and, in particular, HLA-DPB1*04:01 as well as increased homozygosity among responders in our population may explain why so many individuals were able to raise a T cell response to iCope and its homologues in other HCoVs. Of note, IgG screening against spike and nucleocapsid specific epitopes revealed high responses in COVID-19 convalescents as well as multiple cross-reactive responses in healthy donors for a sequence containing the SARS-CoV-2 B cell epitope SFIEDLLF (21) present in iCope and overlapping 73% with iCope. SARS-CoV-2 infection and vaccination with BNT162b2 induced specific antibody production towards this region. Recently, it has been reported that in current vaccine trials, antibodies specific to the S2 portion of spike, in particular, may be involved in the early induction of protection (25, 37) . iCope might serve as a universal conserved coronavirus target for both B cells and T cells. Enhancing the immune response to iCope may have protective effects without the possibility of immune evasion by HCoVs and should be a focus of future studies.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2021. ; https://doi.org/10.1101/2021.04.01.21252379 doi: medRxiv preprint

Stimulation index (stim. index) of reactive CD40L + 4-1BB + CD4 + T cells among PBMCs stimulated with indicated SARS-CoV-2-orfeome peptide pools. Grey labels below indicate proteins exclusive for SARS-CoV-2 (not shared with HCoVs). Grey (COVID- 19) or dark red (Unexposed) dots mark donors with an SI ≥ 3. n = 60 unexposed, n = 59 COVID-19 convalescents. Dotted lines indicate stim. index of 1.5 and 3. *p<0.05, **p<0.01, ***p<0.001 and ns = not significant for p>0.05 (unpaired student's t-test). Results for statistical significance are shown above Unexposed plot. (B) Proportion of individuals with indicated number of SARS-CoV-2-orfeome peptide pool stimulations with a stim. index ≥ 3. (C) Proportion of individuals with stim. index ≥3 for each stimulation in each indicated stimulation combination. (D) To determine the probability of homologous epitopes, a homology score for the comparison of a SARS-CoV-2 antigen with all 4 endemic coronaviruses 229E, NL63, OC43 and HKU1 (isolates N1, N2 N5) is plotted against the mean stim. index of 60 unexposed donors (circles) and 59 COVID-19 convalescents (triangles). For the calculation of the homology score all theoretical possible 9mers in each peptide of a respective PepMix were scored against all 9mers of the complete proteome of all other HCoVs using a PAM30 substitution matrix. The homology score is the percentage of comparisons between the 9mers from the PepMix and all 9mers from the HCoVs with a score above 30. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2021.

Proportions of unexposed individuals aged below 65 (n = 491) and COVID-19 convalescents (n = 174) with S-I or S-II specific responses against HCoV and/or SARS-CoV-2 with a stim. index ≥ 3. (B) Short-term T cell lines derived from OC43 S-I and S-II-reactive primary T cells were restimulated with autologous APC in the presence of OC43 or SARS-CoV-2 spike glycoprotein pool S-I and S-II. Stim. index of CD40L + 4-1BB + CD4 + T cells after re-stimulation is shown. Dotted line indicates stim. index of 3. (C) Stim. index of CD40L + 4-1BB + CD4 + T cells from unexposed or COVID-19 convalescents after stimulation with the single peptide 204_3, the control single peptide 284 or the S-II peptide pool. (D) Anti-204_-1peptide IgG ELISA. The ELISA plates were coated with a 18mer peptide overlapping 11 amino acids with the 204_3 peptide. Serum from unexposed and elderly (>65) individuals as well as COVID-19 convalescents were used at 1:100 dilution. Optical density (OD) of detected IgG antibodies is shown. (E) Distribution of common HLA alleles in definite iCope responders (stim. index ≥ 3) and definite non-responders (stim. index ≤ 1.5), n = 308, +/+ = homozygous, +/-= heterozygous. C, D: *p<0.05, **p<0.01, ***p<0.001 and ns for p>0.05 (Student's t-test).

Stim. index of CD40L + 4-1BB + CD4 + T cells (A), frequencies of HLADR + CD38 + (B), and frequencies of CD3 low (C) in CD40L + 4-1BB + CD4 + T cells after stimulation with SARS-CoV-2 S-I, S-II and CEFX peptide pools of donors prior (baseline) to and at 4 different time points after SARS-CoV-2 infection. CD3 low frequencies are shown for T cell responses with a stim. index ≥1.5. (D) Overview of changes in CD3 low frequency in CD40L + 4-1BB + CD4 + T cells between baseline, follow-up measurement time point 2 (between d10-d16 after symptom onset) and follow-up measurement time point 4 (between d29-d71) (left plot) and statistics (right plot) for baseline and follow-up measurement time point 2 in cross-reactive donors (baseline stim. index ≥ 3, red circles) and non-cross-reactive donors (baseline stim. index ≤ 3, white circles). (E) Stim. index of CD40L + 4-1BB + CD4 + T cells and (F) frequency of CD3 low of CD40L + 4-1BB + CD4 + T cells after stimulation with peptide 204_3 (iCope) or control peptide 284. CD3 low frequencies are shown for T cell responses with a stim. index ≥1.5. (G) Anti-204_-1-peptide IgG ELISA. The ELISA plates were coated with an 18-mer peptide overlapping 11 amino acids with the 204_3 peptide. Sera from baseline and 7 days after symptom onset were used at a 1:100 dilution. Optical density (OD) of detected IgG antibodies is shown. (H) Kinetics of anti-S1-IgG antibody ELISA OD ratios in cross-reactive donors (baseline stim. index ≥ 3, red circles) and non-cross-reactive donors (baseline stim. index ≤ 3, white circles). (I) Correlation of anti-S1-IgG antibody ELISA OD ratio at last sampling time point FU4 (29-71 days after symptom onset, cf. Table 2 ) to the frequency of CD40L + 4-1BB + CD4 + upon S-II stimulation at d0 (baseline, left plot), and correlation of neutralizing antibody titers PRNT50 at last sampling time point FU 4 to frequency of CD40L + 4-1BB + CD4 + upon stimulation with S-II (middle plot) or to stimulation with S-I at d0 (baseline, right plot). (J, K, L) Heat maps with the delta (Δ) of stim. index (J), frequency of CD3 low (K) and frequency of HLADR + CD38 + cells (L) of CD40L + 4-1BB + CD4 + T cells after stimulation with S-II pools of indicated HCoVs. Delta . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2021. ;  is the change of the parameter at the given time point relative to baseline, i.e., white depicts no increase. A, C, D, F, G: *p<0.05, **p<0.01, ***p<0.001 and ns for p>0.05 (Paired Student's t-test). B: *p<0.05, **p<0.01, ***p<0.001 and ns for p>0.05 (repeated measure one-way-ANOVA with Dunnett correction). E: ns for p>0.05 (paired Student's t-test). I: Pearson correlation. Unexposed *** *** *** *** ** *** ns *** *** ns * ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ns ** . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

S P I K E S -I S P I K E S -I I N C A P V M E V E M P O R F 3 a O R F 6 O R F 7 a O R F 7 b O R F 8 O R F 9 b O R F 9 c O R F 1 0 N S P 1 N S P 2 N S P 3 a N S P 3 b N S P

The copyright holder for this preprint this version posted April 5, 2021. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2021. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2021. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2021. ; Table 2 see Table 2 Vaccination . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2021.

This study was approved by the Institutional Review board of the Charité (EA/152/20) and written informed consent was obtained from all participants included (38) . Participants who tested positive for SARS-CoV-2 RNA in nasopharyngeal swabs by RT-qPCR were classified as convalescent donors. All donors were assessed for age, gender, BMI, comorbidities and medications (Table 1) . Convalescent donors were subclassified according to their symptoms into WHO severity grades and information about hospitalization or admission to an intensive care unit (ICU) is given in Table 1 . Day of infection was set as day -3 prior to reported symptom onset. Measurement day post symptom onset is indicated in the graphs or Table 1 . Study participants who reported symptoms typical for a SARS-CoV-2 infection were RT-qPCR tested for virus RNA and positive donors were enrolled for follow-up measurements. Details of the follow-up cohort (age, gender, comorbidities, symptoms, measurement timepoints post symptom onset) are given in Table 2 .

Coronavirus RT-qPCR RNA was extracted by using the MagNA Pure 96 system (Roche, Germany). The viral RNA extraction was performed using from 200 µl swab dilution (Swab suspended in 4.3 ml cobas PCR Media, Roche), eluted in 100µl. Coronavirus detection using 5µl of the RNA eluate was based on two genomic targets (E-and N gene, TIB Molbiol, Berlin, Germany) and detection of the four endemic CoVs was done in a multiplex format (TIB Molbiol, Berlin, Germany). An in-vitro transcribed RNA of equine arteritis virus was used as an internal RT and PCR control. Quantification of SARS-CoV-2 was done using the E-gene target and by applying calibration curves and using serial diluted photometrically quantified in-vitro transcribed RNA as described before (39) . All RT-qPCR's were performed using a LightCycler 480 II (Roche).

Whole blood was collected in lithium heparin tubes for peripheral blood mononuclear cells (PBMC) isolation and SST™II advance (all Vacutainer ® , BD) tubes for serology. SST™II advance tubes were centrifuged at 1000g, 10min and serum supernatant aliquots frozen at -20°C until further use. PBMCs were isolated by gradient density centrifugation according to the manufacturer's instructions (Leucosep tubes, Greiner; Biocoll, Bio&SELL).

Freshly isolated PBMC were cultivated at 5x10 6 PBMC in AB-medium containing RPMI 1640 medium (Gibco) supplemented with 10% heat inactivated AB serum (Pan Biotech), 100 U/ml penicillin (Biochrom), 0.1 mg/ml streptomycin (Biochrom). Stimulations were conducted with 11aa overlapping 15-mer PepMix TM SARS-CoV-2, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1 spike glycoprotein peptide pool 1 or 2 (all from JPT) at concentrations of 1 µg/ml per peptide respectively. SARS-CoV-2 orfeome stimulations were performed with NCAP-1, VEMP-1, VME-1, AP3A (ORF3a), NS6, NS7A, NS7B, NS8, ORF9B, ORF10, Y14 (ORF9c), and the ORF1a/b pools: NSP01, NSP02, NSP03a, NSP03b, NSP04, NSP05, NSP06, NSP07, NSP08, NSP09, NSP10, NSP11, NSP12, NSP13, NSP14, NSP15, NSP16 (all from JPT) at concentrations of 1 µg/ml per peptide respectively. Used control peptide pools were hepatitis . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2021. ; 

Activated cells were enriched from stimulated PBMCs by magnetic cell sorting (MACS). Cells were stimulated with indicated PepMixes in the presence of 1 µg/ml purified anti-CD28 (clone CD28.2, BD Biosciences) and 1 µg/ml purified anti-CD40 (5C3, Biolegend) for 16h followed by staining with CD40L-APC (5C8, Miltenyi) and 4-1BB-PE (4B4-1, BD). The activated cells were enriched with anti-PE MultiSort MicroBeads (Miltenyi) according to manufacturer's instructions. After release of anti-PE beads a second enrichment was performed with anti-APC MicroBeads (Miltenyi). Purity was routinely checked to >80% of alive cells. Feeder cells were obtained from the 4-1BB-PE negative fraction by CD3 MicroBead (Miltenyi) depletion and subsequent irradiation at 50Gy. Enriched CD40L + 4-1BB + cells were co-cultured with feeder cells at a ratio of 1:1 in AB-medium supplemented with 10 ng/ml IL-7 and IL-15 respectively (both from Miltenyi) for 10 d followed by 2 d cytokine starvation. Restimulation in the presence of CD3 depleted, autologous APC was conducted as described above and indicated in the figure legends. For spike glycoprotein epitope identification restimulation was performed with the Epitope Mapping Peptide Set SARS-CoV-2 (JPT) according to the manufacturer's instructions. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2021. ;  SARS-CoV-2 IgG S1 ELISA Anti-SARS-CoV-2 IgG and IgA ELISA specific for S subunit 1 (S1) using a commercial kit (EUROIMMUN Medizinische Labordiagnostika AG) were performed according to the manufacturer's instructions and described previously (40) . Maximum values were set as 10 for IgA.

Neutralization activity of SARS-CoV-2 specific antibodies was assessed with a plaque reduction neutralization test (PRNT) as described before (39) . Vero E6 cells (1.6 x10 5 cells/well) were seeded in 24-well plates overnight. Sera were diluted in OptiPro and mixed 1:1 with 200µl virus (Munich isolate 984) solution containing 100 plaque forming units and incubated at 37°C for 1 hour. Plated Vero cells were incubated with 200µl serum-virus solution.

After 1 hour at 37°C, the supernatants were discarded and cells were washed once with PBS and overlaid with 1.2% Avicel solution in DMEM. After 3 days at 37°C, the supernatants were removed, the cells were fixed with 6% formaldehyde in PBS and stained with crystal violet. All dilutions were tested in duplicates. HRP-coupled, anti-human-IgG secondary antibody (Jackson Immunoresearch) was diluted 1:5000 (Jackson Immunoresearch) and added to the serum samples for 1 h at 30°C, then HRP substrate was added (TMB, Kem-En-Tec). The reaction was stopped by adding sulfuric acid and absorption was measured at 450 nm using a FlexStation 3.

HLA typing has been performed by LABType® CWD assays (One Lambda, West Hills, CA, USA) based on reverse sequence-specific oligonucleotides (rSSO) according to the manufacturer's instructions. Briefly, the HLA genomic region has been amplified individually using locus-specific biotinylated primers for HLA-DRB1, -DQA1, -DQB1, -DPA1 and -DPB1. Amplicons were hybridized to HLA allele-and allele-group-specific probes attached to Luminex® beads. Complementary binding was detected by addition of R-phycoerythrinconjugated streptavidin and acquired using a FLEXMAP 3D flow analyzer (Luminex, Austin, TX, USA). HLA typings were derived as 2-field typing results with the highest probability as referenced in the catalogue of common and well-documented HLA alleles version 2.0.0 33. IEDB Analysis Resource (www.IEDB.org (41, 42), 2.22 method) was used for MHC class II binding prediction of the peptide 204_3 and homologous HCoV epitopes. For the purpose of this analysis, we refer to an individual as 'homozygous' if the two corresponding alleles of the same locus are identical in the first two fields.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2021. ; https://doi.org/10.1101/2021.04.01.21252379 doi: medRxiv preprint Homology score For the calculation of the homology score all possible 9mers were generated for each respective PepMix of SARS-CoV-2. Each of the 9mers was scored against each unique 9mer from the proteomes of the corona viruses 229E, NL63, OC43 and HKU1 (isolates N1, N2, N5) using the PAM30 substitution matrix. The homology score is the percentage of comparisons with a pairwise 9mer-score above 30.

Study data were collected and managed using REDCap electronic data capture tools hosted at Charité (43, 44) . Flow cytometry data were analyzed with FlowJo 10.6 (FlowJo LLC) and statistical analysis conducted with GraphPad Prism 9. If not stated otherwise, data are plotted as mean. N indicates the number of donors. P-values were set as follows: *p<0.05, ** p<0.01, and *** p<0.001.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2021. ; https://doi.org/10.1101/2021.04.01.21252379 doi: medRxiv preprint Fig. S1 : HCoV homology scores and SARS-CoV-2 peptide pool reactivity (A) Similarity between SARS-CoV-2 and the different endemic coronaviruses 229E, NL63, OC43 and HKU1 (isolate N1). Scores were calculated using a PAM30 substitution matrix for all 9mers of the respective antigen against all 9mers of the proteome of SARS-CoV-2. The homology score is the percentage of 9mer pairs with a score above 30. (B) Frequency of donors with reactive T cells against indicated peptide pools in unexposed and COVID-19 convalescents from Fig. 1A with a stim. index ≥ 3. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2021. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 5, 2021. Overlay . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 5, 2021. ; https://doi.org/10.1101/2021.04.01.21252379 doi: medRxiv preprint CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 5, 2021. ; https://doi.org/10.1101/2021.04.01.21252379 doi: medRxiv preprint

Factors associated with COVID-19-related death using OpenSAFELY

Epitope similarity cannot explain the pre-formed T cell immunity towards structural SARS-CoV-2 proteins

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Selective and crossreactive SARS-CoV-2 T cell epitopes in unexposed humans

Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

Immunoreactive peptide maps of SARS-CoV-2

Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

Recent endemic coronavirus infection is associated with less-severe COVID-19

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Human memory T cells: generation, compartmentalization and homeostasis

Primary and secondary anti-viral response captured by the dynamics and phenotype of individual T cell clones. eLife

Origin and Function of Circulating Plasmablasts during Acute Viral Infections

Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection

Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality

Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases

Germinal center reutilization by newly activated B cells

A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center

B Cell Activation State-Governed Formation of Germinal Centers following Viral Infection

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

Cross-reactive memory T cells and herd immunity to SARS-CoV-2

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. The Lancet

Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes

The SARS-CoV Fusion Peptide Forms an Extended Bipartite Fusion Platform that Perturbs Membrane Order in a Calcium-Dependent Manner

Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolution

Virological assessment of hospitalized patients with COVID-2019

A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach

Peptide binding predictions for HLA DR, DP and DQ molecules

The REDCap consortium: Building an international community of software platform partners

Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support

The authors thank Stefan Kolling 

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)